Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Autonomix Medical, Inc.AMIX · Entity 8309 | Director | June 18, 2024 | July 26, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Autonomix Medical, Inc.
Report date June 18, 2024 · Filed July 26, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Warrant (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2029-01-29 | IndirectSee footnote | 110,240 |
Reported balance
After 2024-06-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-18 · Purchase · Acquired 103,990 · Balance 110,240 F1: Includes a portion of 1,600,000 warrants to purchase shares of the Company's common stock that was held by Impulse Medical, Inc., in which Mr. Robins owns 19.5% through Portsmouth Therapeutics, Inc., an entity in which Mr. Robins also owns a 33.33% interest. The shares underlying the warrants are subject to a lockup agreement for a period of six months after January 29, 2024 with respect to 12.5% of the shares issued and twelve months after January 29, 2024 for the remainder of the shares. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes a portion of 1,600,000 warrants to purchase shares of the Company's common stock that was held by Impulse Medical, Inc., in which Mr. Robins owns 19.5% through Portsmouth Therapeutics, Inc., an entity in which Mr. Robins also owns a 33.33% interest. The shares underlying the warrants are subject to a lockup agreement for a period of six months after January 29, 2024 with respect to 12.5% of the shares issued and twelve months after January 29, 2024 for the remainder of the shares.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 18, 2024 Filed Jul 26, 2024 20:06 UTC | Autonomix Medical, Inc. AMIX · Entity 8309 | PurchaseWarrant (Right to buy) · Derivative | 103,990 | $0.00 Strike: $0.00 | $103.99 |
DisclosureSEC source: 0001437749-24-023598 · rdgdoc.xml · derivative · entry 1 Robins David Andrew · CIK 0002007950 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 110,240 Underlying: Common Stock · 103,990 shares Expires 2029-01-29 F1 · derivative.exercise_date: Includes a portion of 1,600,000 warrants to purchase shares of the Company's common stock that was held by Impulse Medical, Inc., in which Mr. Robins owns 19.5% through Portsmouth Therapeutics, Inc., an entity in which Mr. Robins also owns a 33.33% interest. The shares underlying the warrants are subject to a lockup agreement for a period of six months after January 29, 2024 with respect to 12.5% of the shares issued and twelve months after January 29, 2024 for the remainder of the shares. F1 · ownership.direct: Includes a portion of 1,600,000 warrants to purchase shares of the Company's common stock that was held by Impulse Medical, Inc., in which Mr. Robins owns 19.5% through Portsmouth Therapeutics, Inc., an entity in which Mr. Robins also owns a 33.33% interest. The shares underlying the warrants are subject to a lockup agreement for a period of six months after January 29, 2024 with respect to 12.5% of the shares issued and twelve months after January 29, 2024 for the remainder of the shares. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.